奥梅卡姆蒂夫 (Omecamtiv mecarbil) 是一种心脏肌激活剂,在心力衰竭中具有潜在的疗效
Mohammed Kallash1, William H Frishman1,2, Wilbert S Aronow1,2
1Department of Medicine, School of Medicine, New York Medical College, New York, US.
概括
一种新型心脏肌肉素激活剂Omecamtiv mecarbil显著减少了心力衰竭和心血管死亡发生在心力衰竭患者中. 这种创新的治疗方法可以改善心脏收缩能力,而不会增加氧气需求.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 减少喷射分数 (HFrEF) 的心力衰竭是一个重大的全球健康挑战.
- 缩功能受损和心脏输出量减少是HFrEF病理生理学的特征.
研究的目的:
- 评估omecamtiv mecarbil,一种新的心脏肌肉蛋白激活剂,在HFrEF患者中的疗效.
- 评估omecamtiv mecarbil对HFrEF心血管结果的影响.
主要方法:
- 一项主要的临床试验调查了omecamtiv mecarbil在HFrEF患者中的使用.
- 后期分析的重点是重症HFrEF患者.
主要成果:
- 奥梅卡姆蒂夫 (Omecamtiv mecarbil) 显示,HF事件或心血管死亡的复合终点在统计学上显著降低.
- 在患有严重HFrEF的患者中观察到显著的益处.
结论:
- 奥米卡姆蒂夫麦卡尔比尔代表了对HFrEF的有前途的新疗法选择.
- 用激活剂向心肌蛋白提供了一种新的方法来改善心肌收缩性并减少心力衰竭的不良结果.
相关概念视频
Heart Failure Drugs: Inotropic Agents
739
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
739
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
516
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
516
Cardiomyopathy V: Interprofessional Care
38
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
38
Heart Failure V: Medical Management
29
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
29
Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
Myocarditis III: Medical Management
17
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
17


